+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Peptide Drugs Market - Global Forecast 2026-2032- Product Image
Oral Peptide Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Oral Peptide Drugs Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6121564
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Peptide Drugs Market is projected to reach USD 5.20 Billion in 2026. It is expected to continue growing at a CAGR of 6.82%, reaching USD 7.69 Billion by 2032.

Oral Peptide Drugs: Executive Summary and Market Context

Oral peptide drugs are therapeutic products designed to deliver peptide-based medicines through the gastrointestinal tract rather than by injection. Their development addresses a central challenge in peptide pharmacology: protecting molecules from enzymatic degradation while enabling sufficient absorption and consistent exposure. The field spans formulation science, permeation enhancement, gastroprotection, device-enabled dosing, clinical development, manufacturing, and regulatory strategy. Its relevance is increasing as healthcare systems seek effective treatments that are easier for patients to initiate and maintain than injectable regimens.

Formulation, Adherence, and Regulation Are Reshaping Oral Peptide Development

The landscape is shifting from proof-of-concept delivery toward reproducible, patient-centered product design. Developers must balance peptide stability, intestinal permeability, food effects, dose variability, excipient safety, and manufacturing robustness. Oral administration can improve convenience and reduce injection-related barriers, but successful products require clear evidence that exposure, efficacy, and tolerability are consistent in real-world use. Regulatory scrutiny is therefore extending beyond pharmacology to include formulation controls, human-factor considerations, adherence behavior, and long-term safety. Companion diagnostics, digital adherence support, and more flexible clinical trial designs may further influence adoption where they generate clinically meaningful evidence.

Artificial Intelligence Accelerates Discovery, Formulation, and Evidence Generation

Artificial intelligence can support oral peptide programs by predicting peptide stability, transporter interactions, permeation behavior, excipient compatibility, and candidate developability. Machine-learning systems may also help prioritize formulations, interpret high-dimensional pharmacokinetic data, identify patient subgroups, and improve clinical-trial recruitment. Its value depends on representative training data, experimentally validated predictions, transparent model governance, and careful management of bias. AI does not remove the need for laboratory, clinical, quality, and regulatory evidence; instead, it can shorten iteration cycles and focus resources on the most plausible candidates. Organizations should establish controls for data provenance, reproducibility, cybersecurity, and human review before embedding AI into development decisions.

Regional Insights: Delivery Science and Access Conditions Differ Across Geographies

North America combines advanced biotechnology capabilities with demanding evidence and reimbursement expectations, making clinical differentiation, supply reliability, and patient convenience important development priorities. Europe emphasizes harmonized scientific standards alongside country-level health-technology assessment, pricing, and reimbursement requirements. Asia-Pacific benefits from strong pharmaceutical manufacturing and expanding clinical research capacity, while regulatory pathways and healthcare access vary widely across Australia, China, India, Japan, and South Korea. Latin America presents opportunities for broader therapeutic access but requires attention to affordability, local registration, distribution, and cold-chain or handling requirements where applicable. The Middle East is shaped by centralized procurement in some markets, specialist-care infrastructure, and national innovation programs. Africa remains diverse, with access influenced by health-system capacity, procurement mechanisms, specialist availability, and product affordability; partnerships that address training and reliable distribution are particularly important.

Group Insights: Economic and Political Blocs Shape Development and Access

ASEAN markets require country-sensitive regulatory and commercialization planning despite regional cooperation, with differences in reimbursement, clinical infrastructure, and distribution. BRICS members provide varied scientific, manufacturing, and healthcare capabilities, but national registration and procurement rules remain decisive. The European Union offers a coordinated regulatory environment while retaining substantial variation in reimbursement and health-technology assessment across member states. G7 countries generally combine sophisticated research ecosystems with high expectations for evidence, pharmacovigilance, and value demonstration. GCC markets can support centralized purchasing and specialist-care deployment, although registration, tendering, and localization priorities should be assessed market by market. NATO members are not a single healthcare market, yet their shared emphasis on resilience and security makes supply-chain continuity, manufacturing redundancy, and data protection relevant strategic considerations.

Country Insights: Local Evidence and Access Strategy Remain Essential

Australia combines strong clinical standards with a geographically dispersed healthcare system, making reimbursement evidence and distribution planning important. Brazil requires attention to regulatory registration, public and private procurement, affordability, and regional logistics. Canada’s provincial reimbursement structures make comparative clinical and economic evidence central to access. China has substantial scientific and manufacturing capacity, but local regulatory, clinical, data, and procurement requirements must be addressed. France, Germany, Italy, and Spain operate within the European framework while differing in assessment, negotiation, prescribing, and regional implementation. India offers broad pharmaceutical expertise and diverse care settings, requiring careful consideration of affordability, quality systems, and access channels. Japan and South Korea place strong emphasis on regulatory quality, clinical evidence, and local healthcare-system fit. Mexico requires coordinated regulatory, reimbursement, and distribution planning. Russia presents a complex environment in which regulatory, procurement, supply, and geopolitical conditions require ongoing assessment. The United Kingdom uses a distinct regulatory and health-technology-assessment setting, with evidence requirements closely linked to National Health Service adoption. The United States demands rigorous regulatory evidence and payer differentiation, while provider workflow, patient adherence, and benefit design influence practical uptake.

Strategic Priorities for Leaders in Oral Peptide Drugs

Industry leaders should prioritize delivery platforms that demonstrate consistent exposure under clinically relevant conditions, not merely favorable laboratory performance. Development plans should integrate formulation, clinical pharmacology, manufacturing, quality, regulatory, and market-access teams from the outset. Trials should measure adherence, patient preference, food-related use conditions, tolerability, and outcomes that matter to payers and clinicians. Organizations should build regional evidence plans rather than rely on a single global package, especially where reimbursement and health-technology assessment differ. Supply-chain resilience should include qualified suppliers, analytical comparability, manufacturing redundancy, and contingency planning. AI investments should be tied to validated use cases with documented oversight. Finally, leaders should engage regulators, patients, prescribers, payers, and procurement bodies early so that product design reflects real treatment pathways and access constraints.

Research Methodology: Evidence-Based Assessment of the Oral Peptide Landscape

This executive summary uses a structured, qualitative assessment of oral peptide drug development and access conditions. The framework considers delivery technologies, peptide stability and absorption, clinical and regulatory requirements, manufacturing quality, patient usability, reimbursement, healthcare infrastructure, and regional variation. Regional, group, and country perspectives are integrated to identify recurring opportunities and constraints without presenting market estimates, shares, sizing, or forecasts. Interpretations should be validated against current regulatory publications, peer-reviewed research, clinical-trial records, product labels, health-technology assessments, procurement policies, and country-specific access data before being used for investment, development, or commercialization decisions. Because the field evolves rapidly, conclusions should be refreshed as new clinical, regulatory, manufacturing, and safety evidence becomes available.

Conclusion: Converting Oral Delivery Potential into Reliable Patient Value

Oral peptide drugs have the potential to improve treatment convenience, but their success depends on solving interconnected scientific, operational, and access challenges. Durable progress will come from formulations that deliver reliable exposure, evidence that demonstrates meaningful patient and system benefits, manufacturing processes that maintain quality at scale, and regional strategies aligned with local regulation and reimbursement. Artificial intelligence can improve prioritization and efficiency when governed by strong validation and oversight. Leaders that combine delivery science with patient-centered development, resilient operations, and country-specific access planning will be best positioned to translate oral peptide innovation into dependable clinical value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Peptide Drugs Market, by Form
7.1. Introduction
7.2. Capsules
7.3. Oral Solutions
7.4. Oral Suspensions
7.5. Tablets
8. Oral Peptide Drugs Market, by Molecule Type
8.1. Introduction
8.2. Modified Peptides
8.3. Native Peptides
8.4. Peptide Mimetics
9. Oral Peptide Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Oral Peptide Drugs Market, by Application
10.1. Introduction
10.2. Cardiovascular Disorders
10.3. Diabetes
10.3.1. DPP-4 Inhibitors
10.3.2. GLP-1 Analogues
10.3.3. Insulin Peptides
10.4. Gastrointestinal Disorders
10.5. Oncology
10.5.1. Kinase Inhibitors
10.5.2. Peptide Vaccines
11. Oral Peptide Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
11.5. Specialty Centers
12. Oral Peptide Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Oral Peptide Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Oral Peptide Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. AstraZeneca PLC
16.4. Biocon
16.5. Bristol-Myers Squibb Company
16.6. Eli Lilly and Company
16.7. F. Hoffmann-La Roche Ltd.
16.8. i2o Therapeutics
16.9. Intract Pharma
16.10. Ipsen S.A.
16.11. Merck & Co., Inc.
16.12. Novartis AG
16.13. Novo Nordisk A/S
16.14. Oramed Pharmaceuticals Inc.
16.15. Pfizer Inc.
16.16. Protagonist Therapeutics, Inc.
16.17. Sanofi S.A.
16.18. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oral Peptide Drugs Market, Years Considered for the Study
FIGURE 2. Global Oral Peptide Drugs Market, Research Design
FIGURE 3. Global Oral Peptide Drugs Market, Research Framework
FIGURE 4. Global Oral Peptide Drugs Market, Data Triangulation
FIGURE 5. Global Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oral Peptide Drugs Market Size, by Form, 2025 vs 2032 (%)
FIGURE 7. Global Oral Peptide Drugs Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oral Peptide Drugs Market Size, by Molecule Type, 2025 vs 2032 (%)
FIGURE 9. Global Oral Peptide Drugs Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oral Peptide Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Oral Peptide Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oral Peptide Drugs Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global Oral Peptide Drugs Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oral Peptide Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Oral Peptide Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oral Peptide Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Oral Peptide Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oral Peptide Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Oral Peptide Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Oral Peptide Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oral Peptide Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oral Peptide Drugs Market Segmentation & Coverage
TABLE 2. Global Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 4. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Oral Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Oral Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Oral Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Oral Suspensions Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Oral Suspensions Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Oral Suspensions Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 17. Global Modified Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Modified Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Modified Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Native Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Native Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Native Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Peptide Mimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Peptide Mimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Peptide Mimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 27. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 37. Global Cardiovascular Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Cardiovascular Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Cardiovascular Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global DPP-4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global DPP-4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global DPP-4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global GLP-1 Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global GLP-1 Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global GLP-1 Analogues Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Insulin Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Insulin Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Insulin Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Gastrointestinal Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Gastrointestinal Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Gastrointestinal Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Peptide Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Peptide Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Peptide Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. North America Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. North America Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 88. North America Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 89. North America Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. North America Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 91. North America Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 92. North America Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 93. North America Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Latin America Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Latin America Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 96. Latin America Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 97. Latin America Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Latin America Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 99. Latin America Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 100. Latin America Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 101. Latin America Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Europe Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Europe Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 104. Europe Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 105. Europe Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Europe Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. Europe Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 108. Europe Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 109. Europe Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Middle East Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Middle East Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 112. Middle East Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 113. Middle East Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Middle East Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. Middle East Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 116. Middle East Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 117. Middle East Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. Africa Oral Peptide Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Africa Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 120. Africa Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 121. Africa Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Africa Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 123. Africa Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 124. Africa Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 125. Africa Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Global Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. ASEAN Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 129. ASEAN Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 130. ASEAN Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. ASEAN Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. ASEAN Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 133. ASEAN Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 134. ASEAN Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. GCC Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. GCC Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 137. GCC Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 138. GCC Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. GCC Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 140. GCC Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 141. GCC Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 142. GCC Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. European Union Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. European Union Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 145. European Union Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 146. European Union Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. European Union Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 148. European Union Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 149. European Union Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 150. European Union Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. BRICS Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. BRICS Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 153. BRICS Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 154. BRICS Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. BRICS Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. BRICS Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 157. BRICS Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 158. BRICS Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. G7 Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. G7 Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 161. G7 Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 162. G7 Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. G7 Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 164. G7 Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 165. G7 Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 166. G7 Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. NATO Oral Peptide Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. NATO Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 169. NATO Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 170. NATO Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. NATO Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. NATO Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 173. NATO Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 174. NATO Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Global Oral Peptide Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. United States Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 177. United States Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 178. United States Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 179. United States Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. United States Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. United States Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 182. United States Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 183. United States Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Canada Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 185. Canada Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 186. Canada Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 187. Canada Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Canada Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 189. Canada Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 190. Canada Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 191. Canada Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Mexico Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 193. Mexico Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 194. Mexico Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 195. Mexico Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Mexico Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 197. Mexico Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 198. Mexico Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 199. Mexico Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Brazil Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. Brazil Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 202. Brazil Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 203. Brazil Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Brazil Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 205. Brazil Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 206. Brazil Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 207. Brazil Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. United Kingdom Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 209. United Kingdom Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 210. United Kingdom Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 211. United Kingdom Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. United Kingdom Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 213. United Kingdom Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 214. United Kingdom Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 215. United Kingdom Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Germany Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 217. Germany Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 218. Germany Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 219. Germany Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Germany Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 221. Germany Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 222. Germany Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 223. Germany Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. France Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 225. France Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 226. France Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 227. France Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. France Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 229. France Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 230. France Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 231. France Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Russia Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 233. Russia Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 234. Russia Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 235. Russia Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Russia Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 237. Russia Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 238. Russia Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 239. Russia Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Italy Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 241. Italy Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 242. Italy Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 243. Italy Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Italy Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 245. Italy Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 246. Italy Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 247. Italy Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Spain Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 249. Spain Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 250. Spain Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 251. Spain Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Spain Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. Spain Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 254. Spain Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 255. Spain Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. China Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 257. China Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 258. China Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 259. China Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. China Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. China Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 262. China Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 263. China Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. India Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 265. India Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 266. India Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 267. India Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. India Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 269. India Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 270. India Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 271. India Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Japan Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 273. Japan Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 274. Japan Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 275. Japan Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. Japan Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 277. Japan Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 278. Japan Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 279. Japan Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. Australia Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 281. Australia Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 282. Australia Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 283. Australia Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. Australia Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 285. Australia Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 286. Australia Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 287. Australia Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. South Korea Oral Peptide Drugs Market Size, 2017-2032 (USD Million)
TABLE 289. South Korea Oral Peptide Drugs Market Size, by Form, 2017-2032 (USD Million)
TABLE 290. South Korea Oral Peptide Drugs Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 291. South Korea Oral Peptide Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 292. South Korea Oral Peptide Drugs Market Size, by Application, 2017-2032 (USD Million)
TABLE 293. South Korea Oral Peptide Drugs Market Size, by Diabetes, 2017-2032 (USD Million)
TABLE 294. South Korea Oral Peptide Drugs Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 295. South Korea Oral Peptide Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Global Oral Peptide Drugs Market Share, by Key Player, 2025
TABLE 297. Global Oral Peptide Drugs Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • i2o Therapeutics
  • Intract Pharma
  • Ipsen S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Anti-amyloid Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-amyloid Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Specialty Pharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Specialty Pharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Peptide API Market - Global Strategic Business Report - Product Image

Peptide API Market - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

GLP-1 Therapies - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Oral Delivery of Therapeutic Peptides and Proteins - Product Image

Oral Delivery of Therapeutic Peptides and Proteins

  • Book
Copyright © 2002-2026 Research and Markets. All Rights Reserved.